<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biomedical and Pharmacology Journal</journalTitle>
          <issn>0974-6242</issn>
            <publicationDate>2022-12-20</publicationDate>
    
        <volume>15</volume>
        <issue>4</issue>

 
    <startPage>1797</startPage>
    <endPage>1819</endPage>

	 
      <doi>10.13005/bpj/2519</doi>
        <publisherRecordId>46746</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Beta-Lactamases Inhibitors: A Perspective on the Existing and the Potential Admixtures to Synergize Beta-lactams Versus Resistant Superbugs.</title>

    <authors>
	 


      <author>
       <name>Abdel-Nasser El-Shorbagi </name>

 
		
	<affiliationId>2</affiliationId>
      </author>
    

	 


      <author>
       <name>Sachin Chaudhary </name>


		
	<affiliationId>1</affiliationId>

      </author>
    

	 


      <author>
       <name>Anurag Chaudhary</name>

		
	<affiliationId>3</affiliationId>
      </author>
    

	 


      <author>
       <name>Garima Agarwal</name>

		
	<affiliationId>3</affiliationId>
      </author>
    


	 


      <author>
       <name>Prabhash Nath Tripathi</name>

		
	<affiliationId>3</affiliationId>
      </author>
    


	 


      <author>
       <name>Shweta Dumoga</name>

		
	<affiliationId>3</affiliationId>
      </author>
    
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates,</affiliationName>
    

		
		<affiliationName affiliationId="2">Faculty of Pharmacy, University of Assiut, Assiut, Egypt</affiliationName>
    
		
		<affiliationName affiliationId="3">Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, NH-58, Baghpat Road Crossing, Bypass Road, Meerut, Uttar Pradesh, India</affiliationName>
    
		
		
		
	  </affiliationsList>






    <abstract language="eng">β-lactam antibiotics are considered the safest bactericides, and upon wide clinical use of benzyl penicillin G in 1945, outbreaks of resistance came out. The frequent semi-synthetic strategies revealed β-lactam generations that are of broad-spectrum activity. The new agents as well as their concomitant use with known inhibitors of β-lactamases potentiate their effectiveness versus higher numbers of resistant pathogens. However, the extremely resistant pathogens are still representing a burden. Efforts had been continued to find more inhibitors of β-lactamases to combine with β-lactams to provide good management of infections by extremely resistant microbes. The purpose of this work is to overview the conventional and the recently introduced β-lactamases in clinical applications, as well as some reported effective inhibitors of β-lactamases.

The review pinpoints the inhibitors that can be mixed and/or merged with the beta-lactam antibiotics to effectively treat the microbial infections producing resistant-β-lactamases. ClogP for these drugs and candidate inhibitors is introduced as suggestions to open a door for developers to admix derivatives with suitable pharmacokinetics.</abstract>

    <fullTextUrl format="html">https://biomedpharmajournal.org/vol15no4/beta-lactamases-inhibitors-a-perspective-on-the-existing-and-the-potential-admixtures-to-synergize-beta-lactams-versus-resistant-superbugs/</fullTextUrl>

<keywords language="eng">

      
        <keyword>Antibacterial</keyword>
      

      
        <keyword> β-lactamases inhibitors</keyword>
      

      
        <keyword> Clinical investigations</keyword>
      

      
        <keyword> Multi-resistant strains</keyword>
      
</keywords>
  </record>
</records>